Skip to main content
Premium Trial:

Request an Annual Quote

The Ins and Outs of Insolvency

Jeremy Grushcow at The Cross-Border Biotech Blog breaks down how the recent amendments to Canada’s insolvency legislation pertain to intellectual property licenses. He writes that unlike in the U.S., where Section 365 (n) of the bankruptcy code protects licensees in the event that that licensor becomes insolvent, Canadian law has not offered such protection in the past. This has historically forced licensors to establish IP holding companies as separate, bankruptcy-remote structures. Gruschow writes that under the Companies’ Creditors Arrangement Act or Bankrupty and Insolvency Act proposals, “even if an intellectual property license has been successfully disclaimed by an insolvent licensor, the licensee’s right to use, or its ability to enforce a right of exclusive use of, the licensed intellectual property is not affected for the duration of the license agreement (which includes any rights of renewal).” He also offers some cautionary notes regarding the amendments’ terminology.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.